FACT SHEET

MANULIFE DANA EKUITAS OPTIMA SYARIAH USD

FEB 2023

Investment Objective
To provide selected financial investments in accordance with the Syariah Islam principles on various instruments that have been chosen and approved by the Syariah Supervisory Board to suit the values and teachings of Islam.


Fund Information

5 Oct 20 Inception Price USD 0.0626 Fund Size USD 3.553.512.03 47,410,024.37 Number of unit USD 0.0749 Net Asset Value/Unit 4) Fund Currency USD Type of fund Equity Valuation Daily Custodian Bank Bank DBS Indonesia

Annual Management Fee 2.50% MADEOSU IJ Bloomberg Code

Fund Manager PT Manulife Aset Manajemen Indonesia

Risk Classification




Note

- 1) Annualized (1 year = 365 days) and using compound method (for products that have been more than one vear old since inception).
- 2) The benchmark is 80% Indeks Saham Syariah Indonesia + 20% net after tax of average 3-month mudharabah deposit's revenue sharing in USD terms
- 3) Based on GICS (Global Industrials Classification Standard).
- 4) The Net Asset Value / Unit has calculated the costs, including fees related to transaction and transaction settlement as well as administration and recording.

Performance Since Inception

Monthly Performance Last 3 Years





Fund Performance

Performance in USD per (28/02/23)									Yearly Performance								
	1 mo	3 mo	6 mo	YTD	1 yr	3 yr ¹⁾	5 yr ¹⁾	Since Inception 1)		2022	2021	2020	2019	2018	2017	2016	2015
MDEOS USD	-0.93%	-1.45%	-8.21%	0.81%	-4.95%	n/a	n/a	7.94%	MDEOS USD	-6.96%	-3.89%	n/a	n/a	n/a	n/a	n/a	n/a
BM 2)	-1.35%	3.58%	-0.72%	-0.72%	3.14%	n/a	n/a	12.10%	BM 2)	4.91%	4.05%	n/a	n/a	n/a	n/a	n/a	n/a

Top Holdings* & Sector Allocation31

Stock - Adaro Energy Indonesia Tbk PT Stock - AKR Corporindo Tbk PT Stock - Aneka Tambang Tbk Stock - Arwana Citramulia Tbk PT Stock - Bank Aladin Syariah Tbk PT Stock - Barito Pacific Thk PT Stock - Blue Bird Tbk PT Stock - Bukit Asam Tbk PT Stock - Bumi Serpong Damai Tbk PT Stock - Chandra Asri Petrochemical Tbk PT Stock - Charoen Pokphand Indonesia Tbk PT Stock - Cikarang Listrindo Tbk PT Stock - Ciputra Development Tbk PT Stock - Dayamitra Telekomunikasi PT Stock - Erajaya Swasembada Tbk PT Stock - Harum Energy Tbk PT Stock - Indah Kiat Pulp & Paper Tbk PT Stock - Indo Tambangraya Megah Tbk PT Stock - Indocement Tunggal Prakarsa Tbk PT Stock - Indofood CBP Sukses Makmur Tbk PT Stock - Indofood Sukses Makmur Tbk PT *Non Affiliates

Time Deposit - Bank BTPN Svariah

Stock - Medikaloka Hermina Tbk PT Stock - Mitra Adiperkasa Tbk PT Stock - Mitra Keluarga Karvasehat Tbk PT Stock - NFC Indonesia Tbk PT Stock - Pabrik Kertas Tjiwi Kimia Tbk PT Stock - Pakuwon Jati Tbk PT Stock - Perusahaan Gas Negara Tbk PT Stock - PP London Sumatra Indonesia Tbk PT Stock - Semen Indonesia Persero Tbk PT Stock - Summarecon Agung Tbk PT Stock - Surya Citra Media Tbk PT Stock - Telkom Indonesia Persero Tbk PT Stock - Timah Tbk PT Stock - Triputra Agro Persada PT Stock - Unilever Indonesia Tbk PT Stock - United Tractors Tbk PT


Stock - Vale Indonesia Tbk PT

Stock - XL Axiata Tbk PT

Stock - Indosat Tbk PT Stock - Kalbe Farma Tbk PT

Stock - Mayora Indah Tbk PT

Stock - Media Nusantara Citra Tbk PT



Investment Manager Commentary
ia equity market was volatile in February but managed to remain in positive territory, outperforming the global stock market which was down -2.53%, the MSCI Asia Pacific ex-Japan (-6.87%) and MSCI Emerging Market (-6.54%). Global markets braced themselves as US economic data was stronger than expected, fueling expectation that The Fed's monetary policy will remain hawkish. Meanwhile domestically, Indonesia's macroeconomic conditions remain supportive. Growth momentum remain strong with Q4 GDP growth came in better than expected at 5.01% YoY, and FY22 GDP growth at 5.31% YoY, the fastest annual growth since 2013. Bank Indonesia did not raise rates in February at 5.75% and stated that no further rate hike is necessary to contain inflation. Portfolio allocation in energy and consumer discretionary contributed positive attribution, meanwhile allocation in healthcare and materials contributed negative attribution to performance.

Disclaimer: This report is prepared by PT Asuransi Jiwa Manulife Indonesia only for information purposes and not to be used as a sales offering or proposal. Although this report has been prepared meticulously, PT Asuransi Jiwa Manulife Indonesia does not guarantee its accuracy, sufficiency or completeness, and is not responsible for any consequences arising from any actions which are based on the information stated herein. Investments in capital market instruments are subject to various risks which include, but not limited to, market risk, credit risk, interest rate risk, exchange rate risk (particularly in Fund which has allocation in offshore investment instruments in different currencies than the Fund's currency), liquidity risk and other risks which could result in performance volatility. Therefore, the performance of this Fund is not guaranteed, the unit price of each Fund may go up or down and past performance does not necessarily indicative of future performance.

Jiwa Manulife Indonesia are licensed and supervised by the Otoritas Jasa Keuangan (OJK). To learn more about Manulife Indonesia, follow us on Facebook, Twitter, Instagram, YouTube, or visit







